Entergy Corporation vs uniQure N.V. Ordinary Shares — how do they compare? Entergy Corporation trades at $103.92 (market cap $50.16B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: Entergy Corporation is far larger — about 33.9× uniQure N.V. Ordinary Shares's market cap, and Entergy Corporation pays a 2.44% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Entergy Corporation for 13 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ETR | QURE | |
|---|---|---|
Market Cap | $50.16B | $1.48B |
Volume | 2,603,991 | 2,488,780 |
Sector | Utilities | Health |
52-Week High | $117.91 | $70.59 |
52-Week Low | $91.19 | $9.03 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $80.94B | $728.62M |
Dividend Yield | 2.44% | — |
Signals from Pluang's Aura AI — not financial advice
Entergy Corporation (ETR) trades at $104.99, up 0.96% with a bullish technical signal despite overbought RSI readings. The stock shows strong fundamentals with 13.48% net margins and consistent earnings beats in recent quarters. Recent developments include $13.7M in federal grid funding and new data center agreements benefiting customers. Analyst consensus remains strongly positive with 59% buy ratings and a $123.17 price target representing 17% upside potential.
ETR presents a compelling investment case with stable utility operations, improving cash flows, and strategic grid investments. However, elevated valuation multiples and institutional selling activity warrant caution. The stock's proximity to resistance at $105 suggests near-term consolidation may precede further gains if earnings momentum continues through Q3 results.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Entergy is an energy company that operates regulated electric utilities and power generation businesses in the United States. Its generation portfolio includes nuclear, natural gas, and renewable resources.
Read more on ETR →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →